Interestingly, we observed similar overall survival between the TP53-wildtype IDH1R132H subgroup and the TP53-altered IDH1R132X subgroup based on the available size of samples; however, the paramount importance of TP53 status in IDH1R132X glioma requires validation with independent cohorts. This evidence concerns the gene TP53 and glioma.